Why AutoNation’s Results Are Bullish for Automakers
June 4, 2012
Our take on AutoNation’s strong sales and Ford’s possible indigenous branding in China.
Bristol-Myers Squibb Cancer Drug Shows Promise
June 4, 2012
Drug maker Bristol-Myers Squibb (BMY) reported some promising results in a Phase-I trial for a cancer drug that helps the body fight cancer cells by harnessing the patient’s immune system. Link to the trial study results: http://seekingalpha.com/news-article/3046321-investigational-anti-pd-1-immunotherapy-bms-936558-showed-clinical-activity-in-phase-1-trial-of-patients-with-previously-treated-non-small-cell-lung-cancer-metastatic-melanoma-and-renal-cell-cancer Though the sample size was relatively small, the firm’s study showed that the immune system was more responsive while under drug therapy. Nevertheless, this is the first stage of a very long process to approval, and we aren’t too excited about shares at current levels. We prefer Pfizer (PFE) or Teva Pharmaceuticals (TEVA) at current levels on the basis of our Valuentum Buying Index. Please click the following link to view our reports on the pharmaceutical industry: /20110914_1
How Would a Double Dip Impact Retailers?
June 4, 2012
Though we don’t think a double-dip recession in the US is around the corner, we outline our views on how the general economy and employment trends impact same-store-sales performance across the consumer spectrum.
‘The Avengers’ Success Bodes Well for Dividend-Growth Gem Hasbro
May 30, 2012
Dividend-growth portfolio holding Hasbro reported lackluster first-quarter results in April, but the company’s recent success of ‘The Avengers’ could propel earnings in the second and third quarters ahead of consensus estimates. We think Hasbro looks very compelling at current levels.
Monsanto Raises Earnings and Cash-Flow Guidance
May 30, 2012
The world’s largest seed company offered an optimistic outlook for both the remainder of its fiscal 2012 and fiscal 2013. We’ll be taking a look at our fair value estimate for Monsanto and expect to raise it modestly on the news.
RIM Likely to Post First-Quarter Loss, Seeks Strategic Options
May 30, 2012
Research In Motion’s shares look cheap, but its technicals and momentum indicators are atrocious. We’re staying away from this potential value trap.
Revisiting Roundy’s: Dividend Now In Play
May 29, 2012
Roundy’s has declared what seems to be an unsustainable dividend payout, but the firm may still experience significant capital appreciation.
Tiffany Issues Weak First-Quarter Results; Cuts Full-Year Outlook
May 25, 2012
Tiffany reported disappointing first-quarter results that showed decent revenue expansion but weak bottom-line performance. Though we expect to ratchet down our near-term earnings expectations, we don’t expect to make a material change to our fair value estimate.
Hewlett Packard’s Second-Quarter Results Exceed Expectations; Major Changes on the Way
May 24, 2012
Hewlett-Packard posted strong second-quarter results that came in better than consensus expectations. We’re optimistic on HP’s restructuring plans as well as the company’s dirt cheap valuation. However, peers like Intel and Microsoft look like much more attractive investments with better growth potential and near-term catalysts. Both companies also provide investors with better, safer yields, as we think both are best-in-class in chips and enterprise software, respectively.
Dell’s First-Quarter Performance Weighed Down by Encroaching Tablet Competition
May 23, 2012
Dell reported terrible first-quarter results, and we are putting our fair value estimate of the computer maker under review. Though we expect to lower it materially, we maintain that the firm’s shares are significantly underpriced at today’s levels. However, we prefer Apple in the portfolio of our Best Ideas Newsletter.
